Cargando…

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma (MM) is characterized by the clonal accumulation of abnormal plasma cells in the bone marrow. Although current treatments have improved the survival rates of patients with MM, MM remains incurable for most patients due to refractory disease and relapse. Thus, new the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Kaiyan, Jin, Ling, Karolová, Jana, Vorwerk, Jan, Hailfinger, Stephan, Opalka, Bertram, Zapukhlyak, Myroslav, Lenz, Georg, Khandanpour, Cyrus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136620/ https://www.ncbi.nlm.nih.gov/pubmed/37190302 http://dx.doi.org/10.3390/cancers15082373

Ejemplares similares

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
por: Xu, Wendan, et al.
Publicado: (2022)

Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition
por: Vorwerk, Jan, et al.
Publicado: (2022)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

mTOR and MAPK: from localized translation control to epilepsy
por: Pernice, Helena F., et al.
Publicado: (2016)

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma
por: Sandmann, Sarah, et al.
Publicado: (2022)

Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
por: Oertel, Michael, et al.
Publicado: (2023)

Disruption of mTOR and MAPK pathways correlates with severity in idiopathic autism
por: Rosina, Eleonora, et al.
Publicado: (2019)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
por: Bu, Haisong, et al.
Publicado: (2021)

Biphasic regulation of osteoblast development via the ERK MAPK–mTOR pathway
por: Kim, Jung-Min, et al.
Publicado: (2022)

High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid Leukemia
por: Liu, Longlong, et al.
Publicado: (2022)

Molecular profiling of EBV associated diffuse large B-cell lymphoma
por: Frontzek, Fabian, et al.
Publicado: (2023)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

The mTOR Inhibitor Rapamycin Has Limited Acute Anticonvulsant Effects in Mice
por: Hartman, Adam L., et al.
Publicado: (2012)

Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells
por: Miller, Aaron L, et al.
Publicado: (2007)

MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1
por: Brundage, Meghan E., et al.
Publicado: (2014)

GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia
por: Liu, Longlong, et al.
Publicado: (2022)

mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein
por: Guglielmelli, Tommasina, et al.
Publicado: (2015)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth
por: Soliman, Ghada A, et al.
Publicado: (2020)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2020)

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
por: ANDERSEN, NICHOLAS J., et al.
Publicado: (2015)

Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
por: Chauhan, Ashutosh, et al.
Publicado: (2016)

MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade
por: Cai, Qinbo, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Promotion of Ovarian Follicle Growth following mTOR Activation: Synergistic Effects of AKT Stimulators
por: Cheng, Yuan, et al.
Publicado: (2015)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY
por: Arora, Arshi, et al.
Publicado: (2023)

Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iqt6q8dcifpv94neqk9nu4qjrv